Meticuly awarded IP Champion 2025 for innovative 3D Printing of patient-specific implants

Meticuly, a spin-off from Chulalongkorn University, is proud to announce it has won the distinguished Intellectual Property (IP) Champion award for 2025. The award, presented by the Department of Intellectual Property, recognises the company's excellence in the field of medical 3D printing.

The award ceremony took place on Friday, August 15, at the IP Fair in Samyan Mitrtown, where Mr. Jatuporn Buruspat, Minister of the Ministry of Commerce, graciously presented the honour. The award celebrates Meticuly's revolutionary technology for creating a wholly Patient-Specific Implant, a solution that is transforming surgery and elevating the quality of life for patients.

Innovating Surgery with 3D Printing

The award-winning innovation addresses the critical shortcomings of pre-manufactured, standard-sized implants, which often fail to match a patient's unique anatomy. Meticuly’s technology leverages 3D medical imaging (CT/MRI) and advanced 3D printing to design and fabricate a titanium Patient-Specific Implant that conforms perfectly to the patient's body. This bespoke approach increases surgical accuracy, reduces risks, and promotes faster recovery.

A Testament to a Vision

Asst. Prof. Dr. Chedtha Puncreobutr, Chief Technology Officer and Co-founder of Meticuly, stated, "We are deeply honoured to receive the IP Champion award this year. This award is a testament to the commitment of the entire Meticuly team to creating innovations, like our Patient-Specific Implant, that solve real-world medical challenges. We believe intellectual property is a critical foundation for enabling Thai technology to compete on the global stage."

From Local Research to Global Impact

This success in intellectual property aligns with Meticuly's rapid global growth. The company's expertise in medical 3D printing has translated into real-world results, helping over 2,400 patients to date. Our core focus on developing advanced cranioplasty and orthognathic solutions has driven this international expansion, leading to the establishment of entities in the United States, the United Kingdom, and Singapore. Furthermore, our commitment to quality in these critical areas is validated by significant regulatory milestones, including US Food and Drug Administration (US FDA) clearance for three of our main products.